Dr Kate Broderick | Vice President, Research And Development
Inovio Pharmaceuticals | United States

Dr Kate Broderick, Vice President, Research And Development, Inovio Pharmaceuticals

Dr Broderick has a broad background in the product development and device development DNA therapeutic and drug delivery field, with specific expertise in in vivo DNA vaccine animal studies and product development in relation to electroporation.  Her particular area of focus is electroporation device design specifically pertaining to skin delivery and she has been central to the development of Inovio novel prototypes and designs. Dr Broderick has authored and co-authored over 60 peer reviewed article and her group regularly publish their findings and present their work in the public forum at conferences. 
Dr Broderick is also a co-inventor on multiple patents related to DNA vaccine delivery and is principal investigator on grants, awards and contracts from funding bodies such as NIH, Department of Defense and SBIR. She was recently awarded a contract of $56 million from CEPI to fast-track DNA based vaccine candidates for Lassa and MERS through clinical testing. 
Dr Broderick received her PhD from the University of Glasgow in Scotland and performed her post-doctoral research at the University of California, San Diego. She joined Inovio Pharmaceuticals in 2006 where she currently leads a diverse research group focused on enhanced delivery techniques for gene based therapeutics as the Vice President, Preclinical R&D.


Oct 29th Day 1 @ 17:15

A DNA vaccine against MERS vaccine Generates High Levels of Antibodies and Induces Broad-based T Cell Responses in Phase 1 Study

last published: 19/Sep/19 13:06 GMT

back to speakers

Sign Up for Event Updates